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This is a corrigendum for Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

The calculation of variance in the meta-analysis of the overall survival distributions for mice treated with (+)-JQ1 vs. mice treated with vehicle control (Figure 4B) is incorrect. Subsequently, the effect size and the associated *p* value of the meta-analysis are incorrect. The effect size (Hazard Ratio) for this comparison should be HR = 9.16 95% CI \[1.39, 60.54\] (instead of the reported HR = 13.12 95% CI \[1.79, 96.02\]) resulting in a p value of *p* = 0.0215 (instead of the reported *p* = 0.0112).

The language surrounding this comparison in the Results and Discussion section as well as in Figure 4 and the Figure Legend (Figure 4B) have been amended to account for this correction. Additional r code for the meta-analysis can be found on the Open Science Framework: <https://osf.io/x6g87/>.

The corrected Figure 4 is shown here:
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The originally published Figure 4 is also shown for reference:
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The article has now been corrected.
